Key messages on LDL-c biology and therapeutic considerations in relation to CV risk were formulated based on discussions among European lipid experts.
Identification of FH in ACS patients is crucial, as it has an impact on the clinical trajectory. Prof. Hovingh discusses how to classify these patients and their prognosis.
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.
New insights into lipid management have emerged since 2016. Prof. Ray discusses with prof. Mach in which respects the guidelines should be changed.
Prof. Masana explains whether achieving very low LDL-c levels with current treatments is safe and might cause any biological problems.
Prof. Kastelein discusses the biology of LDL with prof. Packard and which strategies are available for LDL-c lowering in CVD prevention in high-risk patients.